Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

The ongoing COVID‐19 pandemic and the emergence of new SARS‐CoV‐2 variants of concern (VOCs) requires continued development of effective therapeutics. Recently, we identified high‐affinity neutralizing nanobodies (Nbs) specific for the receptor‐binding domain (RBD) of SARS‐CoV‐2. Taking advantage of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Teresa R, Schnepf, Daniel, Beer, Julius, Ruetalo, Natalia, Klingel, Karin, Kaiser, Philipp D, Junker, Daniel, Sauter, Martina, Traenkle, Bjoern, Frecot, Desiree I, Becker, Matthias, Schneiderhan‐Marra, Nicole, Ohnemus, Annette, Schwemmle, Martin, Schindler, Michael, Rothbauer, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811630/
https://www.ncbi.nlm.nih.gov/pubmed/34927793
http://dx.doi.org/10.15252/embr.202153865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811630/
https://www.ncbi.nlm.nih.gov/pubmed/34927793
http://dx.doi.org/10.15252/embr.202153865

Ejemplares similares